Fintel reports that on March 4, 2025, Leerink Partners downgraded their outlook for Lexicon Pharmaceuticals (NasdaqGS:LXRX) ...

Lexicon Pharmaceuticals shares are trading lower by 48% Monday morning. The company earlier announced topline results from ...

Needham analyst Joseph Stringer maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company’s shares opened ...

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They ...

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) today and set a price ...

The company has chosen to move ahead to Phase III trials with its 10mg dose after it saw a 1.74-point reduction in pain score ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Shares of Lexicon Pharmaceuticals , Inc. (Nasdaq: NASDAQ: LXRX) plummeted 50% following the announcement of topline results from its Phase 2b PROGRESS study, which evaluated the efficacy of ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Acelyrin rejected a bid by Concentra and Atara cut staff.

Investing.com -- Shares of Lexicon Pharmaceuticals , Inc. (Nasdaq: NASDAQ:LXRX) plummeted 50% following the announcement of topline results from its Phase 2b PROGRESS study, which evaluated the ...